Does Insurance Cover GLP-1 Weight Loss Medications?

Insurance coverage for GLP-1 medications is one of the most confusing, inconsistent, and rapidly changing areas of healthcare. You’re not alone if you’ve spent hours on the phone with your insurance company, heard conflicting answers, or watched coverage change month to month.

The honest answer is this: it depends. Not as an excuse, but as a fact. Your coverage depends on your employer, your specific plan, your state of residence, and the medical indication your provider documents. Some plans cover GLP-1 medications generously. Many cover them only for type 2 diabetes. Others don’t cover them at all.

This page walks through the landscape: what large employers typically offer, what ACA plans include, how Medicaid works by state, and what Medicare covers. We’ll also explain what prior authorization actually involves and when paying out of pocket is the faster, simpler path.

Employer-sponsored insurance

Employer health plans have become the most dynamic part of GLP-1 coverage. From 2023 to 2025, many large employers re-evaluated whether to include GLP-1 weight management, and the results are mixed.

What’s covered: the current landscape

Large employers (500+ employees) have largely made a decision on GLP-1 coverage. The landscape breaks down roughly like this:

• Some employers offer broad coverage for GLP-1 medications for weight management. These are typically companies in tech, finance, and healthcare who see the value in metabolic health.
• Many more cover GLP-1 only for type 2 diabetes. Weight management use is explicitly excluded.
• A smaller portion offer coverage that bridges the gap: they cover GLP-1 for weight management in patients with comorbidities like hypertension, sleep apnea, or cardiovascular disease, but not for “cosmetic” weight loss alone.
• Self-insured employers (who have more flexibility and assume their own claims costs) have been more aggressive about adding coverage than fully-insured employers.

If your employer does cover GLP-1 for weight management, standard restrictions almost always apply.

Standard restrictions (when coverage exists)

When employer plans do cover GLP-1 weight management, they typically require:

• BMI threshold: A BMI of 30 or higher, or 27 or higher if you have a documented comorbidity (high blood pressure, type 2 diabetes, sleep apnea, cardiovascular disease).
• Prior authorization: The provider must submit medical records and justification before the prescription is approved. This is mandatory, not optional.
• Documentation of lifestyle interventions: Many plans require evidence that you’ve already tried diet, exercise, or weight loss counseling. Some require a note from your primary provider stating as much.
• Sometimes medication trials first: Some plans require that you have already been prescribed and tried other weight loss medications (like phentermine or topiramate) before approving GLP-1.
• Quantity and duration limits: Some plans limit you to a certain number of doses per month or restrict how long you can stay on the medication.

The prior authorization reality

Even when your employer’s plan nominally covers GLP-1 weight management, the prior authorization process is where the real gatekeeping happens.

Studies and reports from patients and providers suggest that initial PA denial rates are often 30 to 50 percent^[1]. That means nearly half of requests are denied on the first submission, often for incomplete documentation or because the plan’s criteria are applied inconsistently. Many denials are successfully appealed, but the appeal process adds another 2 to 4 weeks to the timeline.

The result: even if coverage exists on paper, you may spend weeks going back and forth with your insurance company before medication arrives.

ACA marketplace plans

If you get your insurance through the ACA marketplace (also called Healthcare.gov or a state exchange), GLP-1 coverage varies widely by plan and state.

What the ACA requires

The Affordable Care Act requires all plans to cover certain preventive services without cost-sharing: cancer screenings, contraception, mental health services, and a few others^[2]. Weight management medications are not on this list. So ACA plans are not required to cover GLP-1 for weight management at any cost.

What plans actually do

In practice, some ACA plans do cover GLP-1 medications, but:

• Coverage is not universal. Not every Silver, Gold, or Platinum plan includes GLP-1 on its formulary. You have to check your specific plan’s drug list.
• When covered, it’s usually in the specialty tier. GLP-1 medications are almost always listed as Tier 3, 4, or 5 drugs, which means high cost-sharing. You typically pay 30 to 40 percent of the drug cost after your deductible.
• Cost-sharing varies by plan and tier. Even among plans that do cover GLP-1, your out-of-pocket cost can range from $100 to $400+ per month, depending on the plan and your dosage.

Many people on ACA plans who want GLP-1 medication find that the out-of-pocket cost is comparable to or higher than a cash-pay telehealth program.

How to check your plan

Your ACA plan’s formulary is published online. Go to Healthcare.gov (if you purchased through the federal exchange) or your state exchange, find your plan, and download the drug formulary. Search for semaglutide or tirzepatide. If it’s listed, note the tier and cost-sharing details. Then compare that out-of-pocket cost to the all-inclusive price of a cash-pay program.

Medicaid

Medicaid coverage is where state variation becomes most important. Each state manages its own Medicaid program and sets its own drug formulary.

Type 2 diabetes coverage

Most states cover GLP-1 medications for type 2 diabetes under their Medicaid programs. If you qualify for Medicaid and have diabetes, there’s a good chance GLP-1 is available, though prior authorization is common.

Weight management coverage

Coverage for weight management only (without diabetes) is much more limited. As of early 2026:

• A handful of states have explicitly added GLP-1 weight management to their Medicaid formularies. This number is growing but remains small.
• Most states have not, meaning that Medicaid will cover GLP-1 only for diabetes, not for weight management alone.
• Medicaid expansion states (those that expanded eligibility under the ACA) sometimes have different formularies than non-expansion states, so coverage can differ even within the same region.

How to find out your state’s coverage

Your state’s Medicaid agency publishes its formulary online. Search your state + “Medicaid formulary” to find the official list. Look for semaglutide or tirzepatide and note whether weight management is a covered indication.

State-by-state GLP-1 weight management coverage (2026)

As of early 2026, Medicaid coverage for GLP-1 weight loss medications remains limited and is shifting. Here is the current coverage status:

States with Medicaid GLP-1 weight management coverage: A small number of states have explicitly added GLP-1 medications for weight management to their Medicaid formularies. As of January 2026, approximately 13 state Medicaid programs cover GLP-1 for obesity treatment. However, this number has declined from 16 states in late 2025, as some states have discontinued or restricted coverage due to cost.

Recent coverage changes (2025-2026):

• California (Medi-Cal) discontinued coverage effective January 2026
• Pennsylvania Medicaid ended adult coverage for weight loss effective January 2026
• South Carolina discontinued coverage
• New Hampshire discontinued coverage
• Michigan made coverage more restrictive effective January 2026

States without weight management coverage: The majority of states do not cover GLP-1 medications for weight loss alone under Medicaid. These states cover GLP-1 only for type 2 diabetes or other approved medical indications, not for weight management.

The BALANCE Model impact: Beginning May 2026, state Medicaid agencies can join the Medicare BALANCE Model, which will enable CMS to negotiate GLP-1 pricing on behalf of states. This may expand Medicaid coverage for weight management in participating states, but participation is voluntary and the timeline for implementation varies by state.

Key takeaway: If you are on Medicaid and interested in GLP-1 coverage, contact your state Medicaid office directly to ask about current weight management medication coverage. Do not assume coverage is unavailable, but do plan for the possibility that you may need to use a cash-pay program or explore other options if your state does not cover weight loss medications.

Medicare

Medicare coverage for GLP-1 weight management has historically been restricted. However, significant changes are coming through the new BALANCE Model, alongside recent developments in cardiovascular indications.

The Medicare BALANCE Model (launching 2027)

In January 2026, CMS formally announced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model^[3]. This is a major shift in Medicare policy on anti-obesity medications.

What it is: A voluntary payment model that enables Medicare Part D plans to cover GLP-1 medications specifically for weight management, with manufacturer-supported lifestyle programs included at no cost to beneficiaries.

When it launches: Beneficiaries will have access starting July 2026 through a bridge program. Full implementation of the BALANCE Model is scheduled for January 2027.

Who qualifies: Medicare beneficiaries with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related conditions.

Cost to Medicare beneficiaries: Under the BALANCE Model, eligible Medicare beneficiaries will pay $50 per month for a month of GLP-1 medications. All beneficiaries receiving GLP-1s will have access to lifestyle support programs provided by the drug manufacturer at no additional cost.

What this means: For the first time, Medicare will cover anti-obesity medications including GLP-1s (semaglutide, tirzepatide) for weight management as a primary indication. This is a fundamental shift from decades of exclusion based on the 2003 weight loss drug prohibition.

For patients currently on compounded GLP-1s: The BALANCE Model represents a pathway to branded medication coverage beginning in 2027. Patients who cannot currently access insurance may become eligible for Medicare-covered branded GLP-1s through this program.

Current Medicare Part D approach: diabetes and cardiovascular indications

Until the BALANCE Model launches in 2027, traditional Medicare Part D coverage remains limited to specific non-weight-loss indications:

Type 2 Diabetes: Medicare Part D typically covers GLP-1 medications when prescribed for type 2 diabetes.

Cardiovascular risk reduction: The SELECT trial, a large cardiovascular outcomes study, provided evidence that semaglutide reduces cardiovascular events in people with overweight or obesity and existing cardiovascular disease. CMS guidance indicates coverage may be available when prescribed for this indication.

Coverage remains plan-specific and requires prior authorization in most cases. If you are on Medicare, check your specific Part D plan’s formulary or speak with your provider about whether you qualify under current rules.

For a comprehensive guide to Medicare coverage, see our dedicated Medicare Part D and GLP-1 page.

Understanding prior authorization

Prior authorization is the process that determines whether insurance will actually pay for your medication. It’s worth understanding how it works, what the denial process involves, and what improves your chances of approval.

What happens during PA

When your provider prescribes GLP-1, they (or their office staff) submit a prior authorization request to your insurance company. The request includes:

• Your health information: weight, BMI, medical history, comorbidities.
• Documentation that meets the plan’s criteria (BMI threshold, comorbidity, previous lifestyle interventions).
• Sometimes lab results or notes from your primary provider.

Your insurance company (or their contracted pharmacy benefit manager, or PBM) reviews the documentation against the plan’s coverage criteria. This usually takes 3 to 10 business days.

Common reasons for denial

The most frequent reasons for PA denial are:

• Incomplete documentation: Your provider didn’t include enough detail about your medical history or BMI calculation.
• BMI below threshold: Your BMI doesn’t meet the plan’s minimum requirement.
• No documented comorbidities: If the plan requires a comorbidity (like diabetes or sleep apnea), you didn’t have documentation of one.
• No evidence of prior interventions: If the plan requires proof of previous diet or exercise attempts, that documentation was missing.
• Criteria applied inconsistently: The plan’s reviewer applied criteria differently than expected. (This is frustrating because it’s sometimes hard to predict.)

What happens next if you’re denied

You have the right to appeal. An appeal means your provider submits additional documentation or argues why the criteria were met, and a different reviewer (often a provider employed by the insurance company) re-evaluates the request. Many appeals succeed, but the process adds 2 to 4 weeks to the timeline.

Some providers are experienced at getting first-time approvals because they know how to structure the documentation. Others may not be. If you’re stuck in the PA process, it’s worth asking whether your provider has any strategies for improving your chances of approval on the next submission.

When cash-pay is the better choice

For many people, going around insurance entirely and paying out of pocket is actually faster, simpler, and not more expensive than navigating the insurance process.

The Transformation Health all-inclusive program

Transformation Health programs are cash-pay, meaning you don’t use insurance. The cost is transparent and all-inclusive:

• Semaglutide (injectable): $249/month
• Semaglutide (oral): $279/month
• Tirzepatide (injectable or oral): $339/month
• Micro-dosing: $199/month

That monthly fee includes everything: your medication (compounded by a licensed US pharmacy), required lab work, your provider’s care, and medical coaching. There are no hidden fees. You can cancel anytime.

Why this model wins for many patients

Several reasons cash-pay often makes sense:

• No waiting for prior authorization. You complete an online intake, a provider reviews your information within 24 hours, and if appropriate, your medication is prepared and shipped. Total time to first dose: typically 3 to 5 days.
• Certainty on cost. You know exactly what you’re paying and what’s included. No surprise bills for labs, consultations, or other services.
• No denial risk. There’s no insurance company deciding whether you qualify. An independent, licensed provider makes that decision based on your health history.
• Faster pathway. For many people, the cash-pay pathway is actually faster than the insurance PA pathway, even though you’re paying out of pocket.

FSA and HSA

If you have a Flexible Spending Account (FSA) or Health Savings Account (HSA), Transformation Health programs are eligible expenses. This means you can use pre-tax dollars to pay for the program, reducing your effective out-of-pocket cost significantly.

For more details on FSA and HSA eligibility, see our FSA/HSA for Weight Loss Medications page.

The bottom line

Insurance coverage for GLP-1 weight management remains patchy, inconsistent, and slow to approve, even when it exists on paper. That’s not changing anytime soon.

You have two reasonable paths:

1. Work with your insurance. If your employer or plan explicitly covers GLP-1 for weight management and the out-of-pocket cost is low, this can be a good option. Just budget for 3 to 6 weeks of PA wait time and the possibility of a first denial.

2. Pay cash through a telehealth program. If insurance doesn’t cover your indication, if the out-of-pocket cost is high, or if you don’t want to wait for PA, a program like Transformation Health may be faster and equally affordable. You can use FSA or HSA funds to lower your cost.

The right choice depends on your specific insurance plan, out-of-pocket costs, and your timeline. Many patients who start exploring insurance coverage end up choosing cash-pay because the certainty and speed are worth the trade-off.

Citations

[1] Provider and patient survey data on GLP-1 prior authorization denial rates. Per medical evidence compiled from multiple health plan utilization management reports, 2024-2026.

[2] U.S. Centers for Medicare and Medicaid Services. “Preventive Care Services.” https://www.healthcare.gov/preventive-care-adults/

[3] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity Without Previous Cardiovascular Disease.” New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/